Neurocrine Biosciences, Inc. (FRA:NB3)
Germany
· Delayed Price · Currency is EUR 129.20
-0.80 (-0.62%)
At close: Dec 4, 2025
Neurocrine Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 428 | 341.3 | 249.7 | 154.5 | 89.6 | 407.3 | Upgrade
|
| Depreciation & Amortization | 29.7 | 27.1 | 21.3 | 15.6 | 10.9 | 8.6 | Upgrade
|
| Other Amortization | - | - | - | - | 17.3 | 21.4 | Upgrade
|
| Loss (Gain) From Sale of Investments | -7.7 | 10.9 | -46.7 | -27.1 | -13.5 | 17.7 | Upgrade
|
| Stock-Based Compensation | 225.7 | 195.5 | 194.3 | 173.1 | 134.2 | 100 | Upgrade
|
| Other Operating Activities | 128.1 | 39.8 | -56.9 | 90.7 | 1.3 | -288.6 | Upgrade
|
| Change in Accounts Receivable | -246.9 | -39.8 | -89.3 | -162.2 | -28.4 | -30.5 | Upgrade
|
| Change in Inventory | -23.5 | -19.1 | 5.4 | -2.6 | -2.5 | -10.7 | Upgrade
|
| Change in Accounts Payable | 146.6 | 29 | 64.3 | 114.6 | 56.8 | 26.9 | Upgrade
|
| Change in Other Net Operating Assets | 19.6 | 10.7 | 47.8 | -17.2 | -9.2 | -23.6 | Upgrade
|
| Operating Cash Flow | 636.8 | 595.4 | 389.9 | 339.4 | 256.5 | 228.5 | Upgrade
|
| Operating Cash Flow Growth | 33.67% | 52.71% | 14.88% | 32.32% | 12.25% | 55.44% | Upgrade
|
| Capital Expenditures | -43.7 | -38.2 | -28.3 | -16.5 | -23.4 | -10.9 | Upgrade
|
| Cash Acquisitions | - | - | - | -42.7 | - | - | Upgrade
|
| Investment in Securities | -236.1 | -88.6 | -438.8 | -117.9 | -106.8 | 15 | Upgrade
|
| Investing Cash Flow | -279.8 | -126.8 | -467.1 | -177.1 | -130.2 | 4.1 | Upgrade
|
| Long-Term Debt Repaid | - | -308.8 | - | -279 | -0.1 | -186.9 | Upgrade
|
| Net Debt Issued (Repaid) | - | -308.8 | - | -279 | -0.1 | -186.9 | Upgrade
|
| Issuance of Common Stock | 102.1 | 122.1 | 65.3 | 44.7 | 27.5 | 29.1 | Upgrade
|
| Repurchase of Common Stock | -467.7 | -300 | - | - | - | - | Upgrade
|
| Financing Cash Flow | -365.6 | -486.7 | 65.3 | -234.3 | 27.4 | -157.8 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.3 | - | 0.3 | -1.3 | - | - | Upgrade
|
| Net Cash Flow | -8.9 | -18.1 | -11.6 | -73.3 | 153.7 | 74.8 | Upgrade
|
| Free Cash Flow | 593.1 | 557.2 | 361.6 | 322.9 | 233.1 | 217.6 | Upgrade
|
| Free Cash Flow Growth | 34.77% | 54.09% | 11.98% | 38.52% | 7.12% | 64.48% | Upgrade
|
| Free Cash Flow Margin | 22.11% | 23.66% | 19.16% | 21.69% | 20.57% | 20.80% | Upgrade
|
| Free Cash Flow Per Share | 5.80 | 5.37 | 3.58 | 3.27 | 2.38 | 2.23 | Upgrade
|
| Cash Interest Paid | - | 1.6 | 3.8 | 6.6 | 8.6 | 11.6 | Upgrade
|
| Cash Income Tax Paid | 146.6 | 217.5 | 51.5 | 14.4 | 5.1 | 15.3 | Upgrade
|
| Levered Free Cash Flow | 346.19 | 457.98 | 439.25 | 247.63 | 265.75 | 278.59 | Upgrade
|
| Unlevered Free Cash Flow | 346.19 | 457.98 | 439.25 | 247.63 | 264.58 | 277.69 | Upgrade
|
| Change in Working Capital | -153.7 | -19.2 | 28.2 | -67.4 | 16.7 | -37.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.